CCR5 and neoplasm: Leronlimab reduced circulating tumor-associated cells and modulated CCR5-related cytokine production (CCL5, IL-6, and TNF-α), highlighting the potential of CCR5 blockade to reprogram the immunosuppressive microenvironment [234].